comparison
Data were collected at regular intervals by blinded personnel for 48 hours after surgery. Statistical analysis was performed using Wilcoxon's ranked sum test and ?(2) test. P < 0.05 was considered statistically significant.
n/a
n/a
n/a
cumulative incidence of vomiting at 48 hours was 16% in the aprepitant group and 38% in the ondansetron group (P = 0.0149). The incidence of vomiting was also decreased in the aprepitant group at 2 hours (6% vs. 21%, P = 0.0419) and 24 hours (14% vs. 36%, P = 0.0124). From 0 to 48 hours, there was no difference between the aprepitant and ondansetron groups in the incidence of nausea (69% vs. 60%), nausea scores, need for rescue antiemetics (65% vs. 60%), complete response (no PONV and no rescue, 22% vs. 36%), or patient satisfaction with the management of PONV.
combination of aprepitant and dexamethasone was more effective than was the combination of ondansetron and dexamethasone for prophylaxis against postoperative vomiting in adult patients undergoing craniotomy under general anesthesia. However, there was no difference between the groups in the incidence or severity of nausea, need for rescue antiemetics, or in complete response between the groups.
Vigneault, et al. ((2010)
Systematic review of literature
29 Studies involving 1754 patients
MEDLINE, EMBASE, Cochrane, and SCOPUS databases
Literature review summative dose and safety of IVLI should be established before recommending its use.
n/a
n/a
At six hours postoperatively, intravenous lidocaine infusion reduced pain at rest (weighted mean difference [WMD] -8.70, 95% confidence intervals [CI] -16.19 to -1.21), during cough (WMD -11.19, 95% CI -17.73 to -4.65), and during movement (WMD -9.56, 95% CI -17.31 to -1.80). Intravenous lidocaine infusion also reduced opioid requirement (morphine) (WMD -8.44 mg, 95% CI -11.32 to -5.56), time to first flatus (WMD -7.62 hr, 95% CI -10.78 to -4.45), time to first feces (WMD -10.71 hr, 95% CI -16.14 to -5.28), nausea/vomiting (risk ratios = 0.71, 95% CI 0.57-0.90), and hospital length of stay (WMD -0.17 days, 95% CI -0.41 to 0.07).
Rhee, et al. (2010)
Survey.
1191 patients
Surveys
Longitudinal
Interpretive and summative n/a n/a
Postoperative backache and dissatisfaction
The dissatisfaction rate of spinal anesthesia...
Placebos in Clinical Practice REINFORCING MIND-BODY LINK Medical dictionaries define placebo as a non-medication substance, prescribed or given to reinforce the patient's expectation to get well. Research on the effect of placebos is of great significance to healthcare professionals because of their widespread use. That widespread use draws from their effect in the improvement of a symptom or disease without specifically improving the condition under treatment. That effect, called the placebo effect,
Whether someone views something as a placebo or not from a medical standpoint, if it improves the health and well-being of a patient then it is good for that patient, and good for the medical community as a whole (Ambrose, 2007). The second reason for the health care system to allow alternative medicine is that people believe in it in the same way that they believe in placebo pills if
Placebo Drugs One of the most important factors involved in medical trials is probably ethics. Concerns like participant autonomy and informed consent are among the top priorities of the research clinician. This is why the use of placebos in clinical trials produces some murky waters, particularly with issues like the current Ebola crisis in Sub-Saharan Africa. While it is definitely acceptable to use a placebo in some cases, other cases produce
Placebos Proposition Fact (Proposition: Placebos actual benefits patients) 1. You defend a proposition fact relevant significant a future proposition policy, argue values policies essay. IMPORTANT!! 2. The essay carefully strucutured standard parts a formal essay. Proposition of Fact Placebos can have actual benefits to patients Placebos are sham or fake treatments that are given to patients, in place of actual treatment. A doctor can decide to issue this kind of treatment to a
Croop et al. (1997). The overall safety profile of naltrexone is good; however, care must be taken in prescribing the drug to certain patient populations; e.g., naltrexone shows a dose-dependent hepatotoxicity (package insert) and is therefore contraindicated in patients with significant hepatic impairment, which is frequently encountered in alcohol-dependent populations. The clinical trials of naltrexone have typically been conducted in patients without significant impairment in hepatic function. Another consequence of the hepatic
Ginko Biloba Gingko Biloba -- Part I What are the author's general conclusions (summarized) on the effectiveness of Gingko Biloba as a cognitive enhancer? According to the author, effects of Gingko on cognition are perplexing because of its dual actions as following. It's seen improving short-term memory but at the same time it impairs digit recall ability. It slows down mental decline in patients with Alzheimer's disease but has lower dose response curve
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now